Built Through Long-Term Relationships
Our platform connects international technology with Chinese clinical insight, specialized manufacturing, institutional capital, and national commercial delivery.
Selected Technology Relationships
China Clinical Network
MasterVision’s clinical and commercial experience extends across leading public and private ophthalmic institutions throughout China.
Capital Partners
MasterVision has been supported through its development by specialist healthcare and institutional investors, including CD Capital and Qianhai Fund of Funds.
CD Capital
CD Capital is a MedTech-focused venture capital firm led by industry veterans. Established in 2013, CD Capital has managed over $1.4 billion across both USD funds and RMB funds. CD Capital has backed more than 90 great entrepreneurs and disruptive companies to achieve their full potential.
Institutional investor
Qianhai Fund of Funds
Qianhai Fund of Funds (also known as Qianhai Ark Asset Management) is the largest single commercial private equity fund of funds in China, managing approximately $4.02 billion (28 billion RMB). Headquartered at the Shenzhen Stock Exchange Plaza, the firm primarily focuses on venture capital and private equity investments.
Institutional investor
Investor names are shown as part of MasterVision’s financing history and do not imply endorsement of every product, relationship, or website statement.
MasterVision develops and brings promising vision-care innovations into clinical practice turning specialized technologies into accessible solutions for patients and practitioners
Locations
Shanghai
Tianjin
Chongqing
© 2026 MasterVision International. All rights reserved.